Why the study?
Moderate renal ischemia/reperfusion injury is a major cause of kidney failure, prompting investigation into the role of Mas receptor antagonism alone and combined with AT2R antagonism on renal hemodynamic responses to Ang II in male and female rats.
Does Mas receptor antagonist (A779) alter renal hemodynamic responses to Angiotensin II after moderate ischemia/reperfusion in rats?
Does Mas receptor antagonist (A779) alter renal hemodynamic responses to Angiotensin II after moderate ischemia/reperfusion in rats?
Mas receptor blockade alters renal vascular responses to Angiotensin II in female, but not male, rats following moderate renal ischemia/reperfusion injury.
Mas receptor effects on post-ischemic renal hemodynamics appear sex-dependent in rats; leaves open relevance to human AKI.
Moderate renal ischemia/reperfusion (I/R) injury is one of the major causes of kidney failure. We examined the role of Mas receptor (MasR) antagonist (A779) alone and combined with angiotensin II (Ang II) type 2 receptor (AT2R) antagonist (PD123319) on renal hemodynamic responses to Ang II after moderate I/R in male and female rats. Anaesthetized Wistar rats underwent 30 min partial ischemia by reduction of renal perfusion pressure (RPP) and subjected to block vasodepressor receptors followed by Ang II (100 and 300 ng/kg/min) infusion. Mean arterial pressure (MAP), renal blood flow (RBF), and renal vascular resistance (RVR) responses were assessed during graded Ang II infusion at controlled RPP. Thirty min post reperfusion, the Ang II infusion reduced RBF and increased RVR in a dose-related fashion (P < 0.05). However, A779 alone or A779 plus PD123319 infusion increased the RBF and RVR responses to Ang II infusion significantly (P < 0.05) in female but not in the male rats. MasR antagonist altered the RBF and RVR responses to Ang II infusion in female, and these responses were not altered statistically in dual blockade of MasR and AT2R. These findings suggest the important role of Mas receptor in renal vascular response to Ang II in female rats after moderate I/R.
No takes yet. Share an insight, caveat, or question.
Nematbakhsh et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: